The prospective, non-interventional clinical study of carelizumab combined with apatinib in the second-line treatment of advanced non-small cell lung cancer
Latest Information Update: 31 Jul 2020
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2020 New trial record